Secondary Endpoints, Post Hoc Data May Be “Sweet Spot” For Payers
Executive Summary
ATLANTA - Companies should look for the types of clinical trial data which may not be sufficient alone for FDA approval, but could be persuasive to payers making coverage determinations, Schering-Plough's David S. Sugano suggests